Medical Educational Resource
We're accelerating the delivery of treatments and cures.
Novel exon-skipping therapies for patients with DMD: An industry update from Entrada Therapeutics
Activity Snapshot
Activity Type:
Live, Virtual Webinar
Release Date:
Wednesday, March 25, 2026
Expiration Date:
Tuesday, February 24, 2026
Sponsor Information:
Faculty
Natarajan Sethuraman, PhD
President of Research and Development
Entrada Therapeutics
John Brandsema, MD
Children’s Hospital of Philadelphia
Activity Overview:
3:00 PM in Arizona
Discover what’s next in intracellular therapies in this
30-minute live webinar for healthcare professionals. Entrada Therapeutics’ President of Research and Development, Natarajan Sethuraman, PhD, will introduce Entrada Therapeutics and the EEV™ platform, exploring how this approach is being
applied in DMD, with a spotlight on Exons 44 and 45.
John Brandsema, MD, from the Children’s Hospital of Philadelphia, will then explore Entrada’s ongoing clinical trial program for patients with DMD and their evolving pipeline,
followed by a live Q&A with both speakers
